Big Cannabis on Trial: Inside the 320-Page Class Action Accusing MSOs of Lying About Mental Health Benefits

The Complaints: What 573 Pages of Allegations Look Like

Let's start with the sheer scale of these filings, because it tells you something about the seriousness of the legal effort behind them. The Cresco complaint alone is 320 pages. That's not a hastily assembled grievance. That's the product of months, likely years, of investigation, research, and document collection. The Curaleaf complaint adds another 253 pages. Combined, you're looking at 573 pages of allegations that systematically lay out a case against the industry's biggest players.

More than 40 individual plaintiffs have attached their names to these cases. Each of those plaintiffs has a story about purchasing cannabis products from one of the named defendants, consuming those products based on marketing claims about health benefits, and allegedly experiencing serious adverse outcomes. These aren't anonymous complainants. These are real people who are willing to go on record in federal court about what they say happened to them.

The breadth of the complaints suggests that the legal teams behind them are building a narrative that goes beyond individual bad experiences. They're arguing that there was a systematic pattern of deceptive marketing across multiple companies, multiple states, and multiple product lines. If the evidence supports that narrative, the legal exposure for the defendants is enormous.

The Big Tobacco Comparison

Inevitably, commentators are comparing these lawsuits to the landmark tobacco litigation of the 1990s, and the parallel is worth examining even if it's imperfect.

The tobacco cases succeeded because plaintiffs proved that cigarette manufacturers knew their products were harmful and addictive, and that they deliberately marketed them as safe while suppressing internal research that contradicted their public claims. The result was a $206 billion Master Settlement Agreement, sweeping marketing restrictions, and a fundamental transformation of how Americans thought about the tobacco industry.

The cannabis class actions appear to be building a similar framework. The core theory is that the named MSOs knew or should have known that high-potency THC products carry significant mental health risks, but marketed those products as safe and even therapeutic for mental health conditions. If internal documents show that these companies were aware of the risks while publicly promoting mental health benefits, the tobacco parallel becomes very real.

There are important differences, of course. The tobacco cases involved decades of use, millions of victims, and an established scientific consensus about harm. The cannabis cases involve a younger market, less settled science, and a product that many researchers and physicians do believe has legitimate therapeutic applications. The question isn't whether cannabis can ever be beneficial. The question is whether these specific companies made specific claims about specific products that they couldn't or shouldn't have made.

That nuance matters, and it's where the litigation will ultimately be won or lost.

What the Lawsuits Actually Claim

The complaints allege that the four named defendants marketed high-potency THC products as safe treatments for mental health disorders. Not just vague wellness claims, but specific assertions that their products could help with conditions like anxiety, depression, PTSD, and other mental health challenges.

The alleged harms are serious. The complaints cite cases involving psychosis, schizophrenia, suicidal ideation, cardiovascular harm, and cannabis use disorder. These aren't minor side effects. These are life-altering, and in some cases life-threatening, outcomes that the plaintiffs say were a direct result of consuming products they were led to believe were safe and therapeutic.

The focus on high-potency THC is significant and deliberate. The cannabis market has undergone a dramatic potency escalation over the past decade. Products that test at 80, 90, or even 95 percent THC concentration are now readily available in dispensaries nationwide. Concentrates, vape cartridges, and high-potency edibles have become major revenue drivers for the biggest operators. The plaintiffs are arguing that these products carry risks that are qualitatively different from lower-potency cannabis, and that the defendants marketed them without adequate warning.

The Science Debate: High-Potency THC and Mental Health

Here's where things get genuinely complicated, and where intellectual honesty requires acknowledging that the science is not as settled as either side would like.

There is a growing body of research suggesting that high-potency THC products are associated with increased risk of psychotic episodes, particularly in young adults and individuals with predisposing genetic factors. Several large epidemiological studies have found correlations between regular use of high-potency cannabis and first-episode psychosis. The relationship between cannabis and schizophrenia risk has been studied extensively, with most researchers concluding that cannabis can trigger psychotic episodes in vulnerable individuals, though the question of whether it causes schizophrenia in people who wouldn't otherwise develop it remains debated.

Cannabis use disorder is a recognized diagnosis in the DSM-5, and research suggests that higher potency products are associated with faster development of dependence. Cardiovascular risks, while less studied, have been flagged in several recent papers, particularly for inhaled cannabis products.

At the same time, there is also legitimate research supporting therapeutic applications of cannabis for certain mental health conditions. CBD, in particular, has shown promise in clinical trials for anxiety and certain seizure disorders. Some studies have found that lower-dose THC products can provide subjective relief for anxiety and insomnia in some patients.

The crux of the legal argument isn't that cannabis has no therapeutic value whatsoever. It's that the defendants allegedly made sweeping health claims about high-potency THC products without adequate evidence, without appropriate warnings about known risks, and without distinguishing between lower-risk and higher-risk use patterns. You can believe that cannabis has medical applications and still believe that marketing concentrated THC as a mental health treatment is irresponsible.

The Marketing Problem the Industry Created

The cannabis industry has a marketing problem that is largely of its own making, and these lawsuits are the predictable consequence.

For years, the biggest operators have tried to have it both ways. They want cannabis to be treated as medicine when it helps them get licenses, attract investors, and avoid stigma. They want it to be treated as a recreational consumer product when it comes to marketing, pricing, and product development. The result is a marketing landscape where the same company might run a clinical-sounding ad about cannabis for anxiety management alongside a promotion for a 90-percent THC concentrate with a strain name designed to appeal to recreational users.

Budtender recommendations have been a particular area of concern. Dispensary employees routinely make suggestions to customers about which products might help with specific conditions, from insomnia to chronic pain to anxiety. In many cases, these recommendations come from people with minimal training in pharmacology or mental health. The line between customer service and unlicensed medical advice has been blurry at best, and the largest operators have done little to clarify it.

Social media has amplified the problem. Cannabis brands on Instagram, TikTok, and YouTube routinely post content that frames their products as wellness solutions. Testimonials, influencer partnerships, and branded content create an ecosystem of health claims that are often more aggressive than anything the company would put in a formal advertisement. The question of whether companies are legally responsible for the health claims made in their broader marketing ecosystem is one that these lawsuits will likely force the courts to address.

The fundamental issue is that the cannabis industry wanted the credibility that comes with medical positioning without accepting the regulatory constraints that come with making health claims. Pharmaceutical companies that market drugs for mental health conditions must back those claims with rigorous clinical trial data, submit to FDA oversight, and include detailed warnings about side effects. Cannabis companies have been making comparable claims with none of those guardrails.

What This Means for the Cannabis Industry

Regardless of how these specific cases resolve, the message to the cannabis industry is clear: the era of unaccountable health marketing is ending.

The Defendants and Their Likely Response

Cresco Labs, Green Thumb Industries, Verano Holdings, and Curaleaf have not yet responded publicly to the specifics of the complaints in detail. But based on standard industry positioning and the arguments typically deployed in product liability cases, we can anticipate the general outlines of their defense.

They will argue that cannabis is a legal product sold in compliance with state regulations. They will point to the extensive testing and labeling requirements imposed by state cannabis programs. They will argue that consumers are adults who make informed choices and that the risks of cannabis use are widely known. They will challenge the scientific basis of the plaintiffs' claims about causation, arguing that the link between cannabis and the specific harms alleged is not established to the degree required for liability.

They may also argue that the marketing claims identified in the complaints were qualified, that warnings were provided, and that the plaintiffs' own choices and pre-existing conditions contributed to their outcomes. Product liability defense is well-charted territory, and these companies have the resources to mount aggressive legal campaigns.

The wild card is discovery. If internal communications reveal that company executives or scientists knew about risks that weren't disclosed to consumers, the defense becomes much harder. The tobacco cases turned on exactly this kind of evidence, and the plaintiffs' attorneys filing these cannabis cases are almost certainly hoping to find comparable material.

Potential Outcomes and Industry Impact

The range of possible outcomes is wide, and it's worth considering several scenarios.

In the most favorable scenario for the plaintiffs, these cases survive motions to dismiss, proceed through discovery, and either go to trial or produce substantial settlements. If the evidence supports the allegations, the financial exposure could be enormous. Class action settlements in product liability cases involving health claims routinely reach into the hundreds of millions. If the tobacco comparison holds, the numbers could be much larger.

A settlement might also include injunctive relief, meaning court-ordered changes to marketing practices, mandatory warnings on high-potency products, or restrictions on how companies can position cannabis as a mental health treatment. Those structural changes could be more impactful than any financial penalty.

In a less favorable scenario for the plaintiffs, the cases get dismissed on procedural grounds or narrowed significantly during pre-trial motions. Cannabis companies would claim vindication, but the litigation would still have lasting effects on industry marketing practices. Sometimes the mere filing of a case changes behavior, even if the case itself doesn't succeed.

The most likely outcome probably falls somewhere in between: extended litigation that produces settlements without the drama of a full trial, accompanied by industry-wide shifts in marketing practices as companies proactively adjust to avoid similar exposure. That's not as dramatic as a Big Tobacco moment, but it would still represent a meaningful turning point in how the cannabis industry communicates with consumers about the health effects of its products.

A Fair Assessment

As an editorial team that covers cannabis with both enthusiasm and critical honesty, here's our take: these lawsuits raise questions that the industry needs to answer, whether the courts force it or not.

Cannabis is not without therapeutic value. That's supported by research, and we've covered those studies extensively. But therapeutic value in specific contexts, at specific doses, for specific conditions, is very different from blanket marketing that frames high-potency THC as a wellness product. The industry has been too comfortable conflating CBD research with THC product marketing, too quick to extrapolate from limited studies to broad health claims, and too slow to acknowledge the genuine risks associated with heavy use of concentrated cannabis products.

At the same time, the lawsuits deserve scrutiny rather than uncritical celebration. Cannabis is a legal product in the states where these companies operate. Consumers do bear some responsibility for their choices. And the science, while concerning, is still developing. Litigation is a blunt instrument for resolving complex questions about product safety and marketing ethics, and there's a risk that these cases could be weaponized by anti-cannabis interests to undermine the broader legalization movement.

The healthiest outcome would be one where the industry takes the legitimate concerns raised by these lawsuits seriously, adopts more responsible marketing practices voluntarily, and invests in the research needed to give consumers genuinely evidence-based information about what cannabis can and cannot do for their mental health. Whether the industry will do that without being forced to by a court remains an open question.

Frequently Asked Questions

Which companies are named in the class action lawsuits? Cresco Labs, Green Thumb Industries, Verano Holdings, and Curaleaf are the named defendants across two federal class action complaints.

Where were the lawsuits filed? One was filed in the Northern District of Illinois and the other in the District of Connecticut, both on May 4, 2026.

What are the specific allegations? The lawsuits allege that the defendants marketed high-potency THC products as safe treatments for mental health disorders while failing to adequately warn about risks including psychosis, schizophrenia, suicidal ideation, cardiovascular harm, and cannabis use disorder.

How many plaintiffs are involved? More than 40 individual plaintiffs are named across both complaints.

Why are people comparing this to Big Tobacco? The comparison centers on the allegation that major companies knowingly marketed potentially harmful products as safe, a pattern that mirrors the core claims in the 1990s tobacco litigation.

Does this mean cannabis is dangerous? These lawsuits focus specifically on high-potency THC products and the marketing claims made about them, not cannabis in general. The science on cannabis and mental health is complex, with evidence supporting both therapeutic applications and potential risks depending on the product, dosage, and individual factors.

What could happen if the companies lose? Potential outcomes include financial settlements, court-ordered changes to marketing practices, mandatory warnings on high-potency products, and industry-wide shifts in how cannabis companies communicate about health effects.

Will this affect cannabis legalization? These lawsuits target specific marketing practices, not the legality of cannabis. However, the litigation could influence how regulators approach marketing oversight in legal cannabis markets.